
Hyperfine, Inc.
74
Recent developments include record revenue reporting for Q3 2026 and detailed earnings call transcripts for Q1 through Q3 2026, highlighting operational and financial performance.
- Hyperfine, Inc. reported record $6.0 million revenues for the third quarter of 2026 [N2].
- The company’s Q3 2026 earnings call transcript provides detailed insights into financial and operational results [N1].
- Q2 2026 earnings call and highlights disclosed operational performance and financial results [N3][N4].
- The company reported a Q2 2026 loss and lagged revenue estimates as disclosed in earnings reports [N5].
- Nasdaq issued a notice regarding the company’s failure to meet minimum bid price requirements, with a compliance deadline in March 2027 [S2].
Hyperfine, Inc. operates as a publicly traded company with a focus on medical technology, as indicated by its recent earnings calls and revenue reports. The company has demonstrated revenue growth with a record $6.0 million reported in Q3 2026. Its financial position as of September 30, 2026, shows strong liquidity with a current ratio of 5.1 and cash ratio of 3.6, supported by $37.87 million in cash and equivalents. Despite these strengths, the company reported a net loss of $5.98 million for the quarter. Hyperfine faces regulatory risk related to Nasdaq listing requirements due to its stock price falling below $1.00 per share for an extended period, triggering a compliance period to regain the minimum bid price.
Hyperfine, Inc. reported record revenues of $6.0 million for the third quarter of 2026, according to recent earnings disclosures. The company’s latest SEC 10-Q filing for the period ending September 30, 2026, shows cash and cash equivalents of $37.87 million and a current ratio of 5.1, indicating strong liquidity. However, the company reported a net loss of $5.98 million for the same period with an EPS of -$0.06. Hyperfine received a Nasdaq notice for not meeting the minimum bid price requirement but has until March 16, 2027, to regain compliance. Financial figures are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice.
The company has demonstrated revenue growth with a record $6.0 million in Q3 2026 and maintains strong liquidity with a current ratio of 5.1 and cash ratio of 3.6 as of September 30, 2026. Detailed earnings call transcripts provide transparency into operations and financial performance. The company’s ability to manage its Nasdaq listing compliance within the allowed period could support continued market access and investor engagement.
Hyperfine reported a net loss of $5.98 million for Q3 2026 and an EPS of -$0.06, indicating ongoing profitability challenges. The company received a Nasdaq notice for failing to meet the minimum bid price requirement, posing a risk of delisting if compliance is not regained by March 16, 2027. Limited disclosure on sector and industry specifics constrains visibility into competitive positioning and market dynamics.
Hyperfine’s moat appears to be based on its specialized medical technology offerings and recent revenue growth, supported by detailed earnings disclosures. The company’s liquidity position provides operational flexibility. However, the lack of disclosed industry and sector details limits visibility into competitive advantages or barriers to entry. The company’s ability to maintain Nasdaq listing compliance is a key factor in sustaining investor confidence and access to capital markets.
• Nasdaq Listing Compliance Risk: The company received a notice from Nasdaq for not meeting the minimum bid price requirement of $1.00 per share, with a compliance deadline of March 16, 2027. Failure to regain compliance could result in delisting, adversely affecting liquidity and capital raising ability.
• Profitability Challenges: Hyperfine reported a net loss of $5.98 million for the quarter ending September 30, 2026, with negative EPS, indicating ongoing challenges in achieving profitability.
• Limited Sector and Industry Disclosure: The absence of detailed sector and industry information limits external visibility into the company’s competitive environment and market risks.
Business trends: Record quarterly revenues and detailed earnings disclosures indicate operational transparency and growth focus.
Execution milestones: Managing Nasdaq listing compliance and improving profitability are critical near-term milestones.
Key risks: Nasdaq delisting risk due to low stock price, ongoing net losses, and limited sector visibility.
High visibility
Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).
- Hyperfine, Inc. is a publicly traded company with ticker HYPR.
- The company reported record revenues of $6.0 million for the third quarter of 2026.
- The latest SEC filing is a 10-Q for the period ending September 30, 2026, filed on November 9, 2026.
- As of September 30, 2026, Hyperfine had cash and cash equivalents of $37.87 million and current assets of $53.75 million.
- Current liabilities as of September 30, 2026, were $10.53 million, resulting in a current ratio of 5.1 and a cash ratio of 3.6, indicating strong liquidity.
- Net income for the quarter ending September 30, 2026, was a loss of $5.98 million, with basic and diluted EPS of -$0.06 per share.
- The company has received a Nasdaq notice for not meeting the minimum bid price requirement of $1.00 per share but has a compliance period until March 16, 2027, to regain compliance.
- Recent earnings call transcripts and highlights are available for Q1, Q2, and Q3 2026, providing detailed operational and financial insights.
- The company’s stock price was $1.281 as of March 18, 2026.
- The company’s business and financial condition are subject to risks including potential Nasdaq delisting if minimum bid price requirements are not met.
- The company’s recent news coverage includes detailed earnings call transcripts and revenue reports from Nasdaq.com.
- Financial figures are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice.
Generated 2026-11-10
- N1
- N3
- S1 | 2026-03-18 | 10-K
- S2 | 2026-11-09 | 10-Q
- N1 | 2026-11-10 | www.nasdaq.com | Hyperfine (HYPR) Q3 2026 Earnings Call Transcript | https://www.nasdaq.com/articles/hyperfine-hypr-q3-2026-earnings-call-transcript
- N2 | 2026-11-10 | www.nasdaq.com | Hyperfine, Inc. Reports Record $6.0 million Revenues for Third Quarter 2026 | https://www.nasdaq.com/articles/hyperfine-inc-reports-record-60-million-revenues-third-quarter-2026
- N3 | 2026-08-14 | www.nasdaq.com | Hyperfine (HYPR) Q2 2026 Earnings Call Transcript | https://www.nasdaq.com/articles/hyperfine-hypr-q2-2026-earnings-call-transcript
- N4 | 2026-08-07 | www.nasdaq.com | Hyperfine Q2 Earnings Call Highlights | https://www.nasdaq.com/articles/hyperfine-q2-earnings-call-highlights
- N5 | 2026-08-06 | www.nasdaq.com | Hyperfine, Inc. (HYPR) Reports Q2 Loss, Lags Revenue Estimates | https://www.nasdaq.com/articles/hyperfine-inc-hypr-reports-q2-loss-lags-revenue-estimates
- N6 | 2026-08-05 | www.nasdaq.com | RxSight, Inc. (RXST) Reports Q2 Loss, Beats Revenue Estimates | https://www.nasdaq.com/articles/rxsight-inc-rxst-reports-q2-loss-beats-revenue-estimates
- N7 | 2026-08-04 | www.nasdaq.com | OrthoPediatrics (KIDS) Reports Q2 Loss, Tops Revenue Estimates | https://www.nasdaq.com/articles/orthopediatrics-kids-reports-q2-loss-tops-revenue-estimates
- N8 | 2026-07-29 | www.nasdaq.com | Glaukos (GKOS) Reports Q2 Loss, Tops Revenue Estimates | https://www.nasdaq.com/articles/glaukos-gkos-reports-q2-loss-tops-revenue-estimates
This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Generated by Valye SEC Pipeline Engine
.gif)


